Videos

Chirag Shah, MD, MPH shares insight into factors influencing the prognosis of patients with ovarian cancer.

Chirag Shah, MD, MPH, an expert in gynecologic oncology, provides an overview of the case of a 67-year-old woman with ovarian cancer by reviewing the patient’s initial presentation, clinical work-up, and treatment.

Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent results of the PRIMA and NOVA trials of niraparib in patients with ovarian cancer.

Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.

An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.

Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.

An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.

Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.

An expert hematologist-oncologist reviews the standard of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM and explores the role of quadruplet induction regimens.

Clifton C. Mo, MD, presents the case of a 79-year-old woman with R-ISS stage I multiple myeloma and shares his initial impressions.

Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.

Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Thomas Hutson, DO, PharmD suggests the areas new research for non-clear cell renal cell carcinoma should explore.

Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.

Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).

An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.

Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.

Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.

Experts in the field of gastrointestinal stromal tumors (GISTs) discuss the role of sequencing therapy in the frontline and later-line settings.

Experts discuss advances in gastrointestinal stromal tumors (GIST) and dive into the evolving landscape and ongoing unmet needs.

William G. Wierda, MD, PhD, discusses the synergy between ibrutinib and venetoclax in patients with chronic lymphocytic leukemia.

Citing clinical pearls from her own experience in working with patients with relapsed/refractory follicular lymphoma, Kami Maddocks, MD, gives advice to colleagues in their efforts to combat follicular lymphoma.

Kami Maddocks, MD, lists the future directions and unmet needs present in treating relapsed/refractory follicular lymphoma.

The challenges faced in treating patients beyond second-line treatment are addressed. Kami Maddocks, MD, reviews the frequency of patients who require third- and fourth-line treatment, in addition to the factors that affect treatment decisions in later lines of therapy.

Considerations for subsequent treatment options in the second-line setting for patients with follicular lymphoma are reviewed by an expert hematologist.

Kami Maddocks, MD, highlights what findings may trigger a change in therapy or the introduction of a new agent into a patient’s current treatment.

Kami Maddocks, MD, explains the factors surrounding when and why a physician may choose to introduce maintenance therapy for a patient with follicular lymphoma.

An expert hematologist discusses choosing first-line therapy options for patients with follicular lymphoma.

Kami Maddocks, MD, presents the patient diagnosis and treatment history of a 74-year-old-man with relapsed/refractory follicular lymphoma.

Kami Maddocks, MD, reviews the case of a 74-year-old man with relapsed/refractory follicular lymphoma and discusses current treatment options.